- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Celltrion to Buy Back Additional 100 Bil. Won in Shares to Boost Shareholder Value | 2 | BusinessKorea | ||
| Do | Celltrion to repurchase 100 bln won in shares to boost shareholder value | 1 | Yonhap News | ||
| Mo | Celltrion Opens UK Headquarters in Uxbridge | 1 | Contract Pharma | ||
| 20.06. | Celltrion deepens global ties, unveils R&D vision at Bio U.S.A | 1 | Korea Herald | ||
| 19.06. | Celltrion UK: Celltrion opens new UK headquarters in Uxbridge, UK | 261 | Business Wire | New office located in the heart of Uxbridge underscores Celltrion's long-term business commitment in the UK
Celltrion UK has officially opened its new UK headquarters at the Charter Building... ► Artikel lesen | |
| 17.06. | FDA approves new presentation of Celltrion's SteQeyma for paediatric psoriasis | - | PMLiVE | ||
| 17.06. | Samsung, Celltrion, SK lead Korea's largest showing at Bio U.S.A 2025 | 1 | Korea Herald | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| 16.06. | FDA Approves New Pediatric Presentation Of Celltrion' STEQEYMA For Psoriasis And Psoriatic Arthritis | - | RTTNews | ||
| 16.06. | Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA (ustekinumab-stba), expanding dosing options for pediatric patients | 139 | PR Newswire | Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO)... ► Artikel lesen | |
| 13.06. | Celltrion's Cancer Drug Herzuma Achieves 75% Market Share in Japan | 1 | BusinessKorea | ||
| 11.06. | Onconic Therapeutics Partners with Celltrion for Cancer Drug Development | 3 | BusinessKorea | ||
| 28.05. | Celltrion's Remsima SC hits fivefold growth in Europe | 2 | Korea Herald | ||
| 28.05. | 32 Stocks, Including Korea Zinc and Celltrion, to be Removed from Value-Up Index | 1 | BusinessKorea | ||
| 27.05. | Celltrion strives to boost stock price | 1 | Korea Times | ||
| 27.05. | Celltrion shares rise after bonus issue announcement | 1 | Korea Economic Daily | ||
| 22.05. | Celltrion's YUFLYMA Granted Expanded Interchangeable Designation | 2 | Contract Pharma | ||
| 22.05. | Celltrion's Steqeyma gains wider insurance coverage in U.S. | 1 | Korea Herald | ||
| 22.05. | Minority Shareholders of Celltrion Launch Activist Campaign | 4 | BusinessKorea | ||
| 22.05. | Celltrion Welcomes U.S. Drug Price Reduction Measures | 1 | BusinessKorea | ||
| 22.05. | Celltrion's YUFLYMA (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths | 217 | PR Newswire | YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1]
Celltrion previously received... ► Artikel lesen |
1 2 3 4 5 Weiter >>
123 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
Das Unternehmen CELLTRION INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.